TMO vs GLW vs RGEN Stock Comparison

Thermo Fisher Scientific, Corning and Repligen Prices as of Oct 23, 2026 Peers: Industry group
GLW Corning Inc /Ny
$123.63 -20.0% 1M +44.0% 1Y
Market cap
$109.74B
P/E
57.8x
Revenue (TTM)
$16.96B
Div. yield
0.01%
Specialty Chemicals Basic Materials
5 wins
RGEN Repligen Corp
$176.93 -4.1% 1M +7.1% 1Y
Market cap
$10.14B
P/E
244.2x
Revenue (TTM)
$785.10M
Div. yield
–
Life Sciences Tools Healthcare
2 wins

Head to Head

12 decided of 12

Thermo Fisher Scientific leads on 5 of the 12 questions below (Thermo Fisher Scientific 5, Corning 5, Repligen 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTMOGLWRGENLeader
Larger companyMarket capitalisation $254.18B $109.74B $10.14B TMO
Cheaper on earningsLower P/E, profitable companies only 36.5x 57.8x 244.2x TMO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.1x 35.8x 91.2x TMO
Faster revenue growthRevenue growth, trailing twelve months +7.2% +19.4% +16.5% GLW
More profitableNet margin, trailing twelve months 15.0% 11.2% 5.3% TMO
Better return on capitalReturn on invested capital 7.9% 10.4% 1.9% GLW
Less leveragedLower net debt / EBITDA 3.5x 1.5x -1.6x RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.00% GLW
Better 1-year returnPrice return, last 12 months +17.8% +44.0% +7.1% GLW
Better 5-year returnAnnualised price return, 5 years +1.9%/yr +26.5%/yr -8.4%/yr GLW
Less volatileAnnualised volatility, 1 year 29.8% 74.5% 46.3% TMO
Higher overall scoreMean of the five percentile scores vs peers 59/100 57/100 66/100 RGEN

Percentile Scorecard

TMOGLWRGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTMOGLWRGEN
Valuation 60 #93 of 228 19 #76 of 94 53 #108 of 228
Growth 35 #144 of 222 99 #2 of 92 56 #98 of 222
Profitability 83 #37 of 210 81 #18 of 89 70 #63 of 210
Financial Health 28 #174 of 241 59 #40 of 97 80 #49 of 241
Shareholder Returns 88 #18 of 138 29 #50 of 70 70 #42 of 138
Overall 59 57 66
  • TMO ranked among 248 companies in Medical Devices and Diagnostics
  • GLW ranked among 99 companies in Chemicals
  • RGEN ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTMOGLWRGENSPY
1 month +1.2%-20.0%-4.1% -1.0%
3 months +18.6%-15.7%+34.1% +2.9%
6 months +43.5%-29.7%+50.5% +6.4%
Year to date +16.3%+41.2%+8.0% +11.4%
1 year +17.8%+44.0%+7.1% +13.1%
3 years +47.1%+360.3%+26.6% +79.4%
3 years, per year +13.7%+66.4%+8.2% +21.5%
5 years +10.1%+223.4%-35.7% +67.7%
5 years, per year +1.9%+26.5%-8.4% +10.9%
10 years +347.3%+419.0%+504.9% +255.2%
10 years, per year +16.2%+17.9%+19.7% +13.5%

Risk

MeasureTMOGLWRGENSPY
Volatility, 1Y 29.8%74.5%46.3% 12.7%
Downside volatility, 1Y 28.3%75.7%46.9% 12.7%
Beta vs S&P 500, 1Y 0.593.011.18 1.00
Return / volatility, 1Y 0.600.590.15 1.03
Max drawdown, 5Y -41.5%-51.6%-66.2% -25.4%
From 52-week high -3.3%-51.6%-9.1% -2.5%
52-week high $696.55$255.69$194.57 $779.14
52-week low $438.34$78.03$102.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTMOGLWRGEN
P/E now vs peer median 35.9xmedian 30.7x 56.1xmedian 21.5x 240.3xmedian 30.7x
P/S now vs peer median 5.4xmedian 3.0x 6.3xmedian 1.4x 12.7xmedian 3.0x
EV/EBITDA now vs peer median 25.9xmedian 17.7x 27.9xmedian 12.4x 60.5xmedian 17.7x
P/FCF now vs peer median 34.0xmedian 23.7x 44.5xmedian 15.5x 89.2xmedian 23.7x
P/B now vs peer median 4.7xmedian 2.4x 8.1xmedian 1.6x 4.7xmedian 2.4x
PEG now vs peer median 4.27median 0.96 1.28median 1.70 -7.90median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTMOGLWRGEN
Revenue $46.34B $16.96B $785.10M
Gross profit $18.91B $6.17B $422.67M
Operating income $8.15B $2.60B $64.61M
Net income $6.99B $2.07B $41.54M
Free cash flow $7.32B $2.40B $111.97M
R&D $1.40B $1.14B $56.17M
EPS (diluted) $18.78 $2.17 $0.73
Cash & equivalents $4.06B $2.50B $606.78M
Total debt $42.55B $33.16B $551.05M
Shares (diluted) 371.00M 875.00M 56.64M
Enterprise value $233.20B $102.31B $7.03B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTMOGLWRGEN
P/E 35.9x 56.1x 240.3x
P/FCF 34.0x 44.5x 89.2x
P/Operating cash flow 27.6x 27.2x 74.0x
P/S 5.4x 6.3x 12.7x
P/B 4.7x 8.1x 4.7x
P/Tangible book 7.3x 8.5x 5.7x
EV/EBITDA 25.9x 27.9x 60.5x
EV/EBIT 35.3x 43.3x 150.5x
EV/Revenue 6.2x 6.6x 12.4x
EV/FCF 39.3x 47.0x 86.9x
EV/Operating cash flow 31.9x 28.7x 72.1x
PEG (3Y EPS CAGR) 4.27 1.28 -7.90

Growth

14 metrics
MetricTMOGLWRGEN
Revenue growth (1Y) 7.2% 19.4% 16.5%
Revenue CAGR (3Y) 2.1% 8.4% 3.3%
Gross profit growth (1Y) 6.2% 24.9% 40.6%
Gross profit CAGR (3Y) 3.0% 15.6% 4.2%
Operating income growth (1Y) 10.0% 51.7% 370.8%
Operating income CAGR (3Y) 6.7% 39.6% -21.7%
Net income growth (1Y) 6.2% 128.4% 400.4%
Net income CAGR (3Y) 6.9% 44.1% -30.6%
EPS growth (1Y) 7.8% 129.3% 399.7%
EPS CAGR (3Y) 8.4% 43.7% -30.4%
Operating cash flow growth (1Y) 18.9% 79.5% 2.1%
Operating cash flow CAGR (3Y) 5.4% 27.4% -3.2%
Free cash flow growth (1Y) 18.6% 100.6% 2.8%
Free cash flow CAGR (3Y) 7.7% 111.0% 3.9%

Profitability

14 metrics
MetricTMOGLWRGEN
Gross margin 40.8% 36.4% 53.8%
EBITDA margin 23.9% 23.8% 20.5%
Operating margin 17.6% 15.3% 8.2%
Pretax margin 16.5% 14.2% 6.6%
Net margin 15.0% 11.2% 5.3%
FCF margin 15.8% 14.1% 14.3%
Operating cash flow margin 19.5% 23.1% 17.2%
Return on equity 13.4% 16.3% 2.0%
Return on assets 6.2% 6.5% 1.4%
Return on invested capital 7.9% 10.4% 1.9%
Return on capital employed 8.3% 10.0% 2.3%
Asset turnover 0.4x 0.5x 0.3x
Cash conversion (OCF / net income) 1.3x 1.9x 3.2x
Stock comp / revenue 0.7% 2.5% 4.2%

Financial Health

11 metrics
MetricTMOGLWRGEN
Debt / assets 37.6% 25.7% 18.7%
Debt / equity 0.8x 0.6x 0.3x
Net debt / EBITDA 3.5x 1.5x -1.6x
Debt / FCF 5.8x 3.5x 4.9x
Liabilities / assets 53.4% 60.2% 28.4%
Equity / assets 46.6% 39.8% 71.6%
Interest coverage 5.6x 7.3x 2.9x
Current ratio 1.6x 1.8x 9.1x
Quick ratio 1.0x 0.9x 7.3x
Cash ratio 0.3x 0.4x 6.1x
Altman Z-score 3.98 4.89 8.14

Shareholder Returns

7 metrics
MetricTMOGLWRGEN
Dividend yield 0.3% 0.9% –
Net buyback yield 2.0% -0.5% 0.0%
Shareholder yield 2.3% 0.4% 0.0%
Payout ratio (earnings) 9.5% 47.8% –
Payout ratio (FCF) 9.0% 41.4% –
Dividend growth (1Y) 8.5% -0.3% –
Dividend CAGR (3Y) 10.8% 0.9% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTMOGLWRGEN
Forward P/E 26.1xFY2026 35.8xFY2026 91.2xFY2026
EPS, next fiscal year $25.77FY2026 $3.45FY2026 $1.94FY2026
EPS growth, next FY +12.7%FY2026 +36.9%FY2026 +13.5%FY2026
EPS growth, the year after +1.8% +23.2% +29.4%
Revenue, next fiscal year $49.99BFY2026 $18.31BFY2026 $772.56MFY2026
Revenue growth, next FY +12.2%FY2026 +11.6%FY2026 +4.6%FY2026
Revenue growth, the year after -2.9% +30.7% +35.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTMOGLWRGEN
Held by institutions 90.2% 73.0% 100.0%
Institutions holding 2,621 2,680 482
Change in shares held, QoQ +0.8% +3.5% +1.2%
Institutions buying 1,141 1,474 272
Institutions selling 1,144 949 141
Buyers to sellers 1.00 1.55 1.93

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TMOGLWRGEN
TMO 1.00 -0.03 0.67
GLW -0.03 1.00 0.00
RGEN 0.67 0.00 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, TMO, GLW and RGEN?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Thermo Fisher Scientific (TMO) $254.18B, Corning (GLW) $109.74B, Repligen (RGEN) $10.14B.

Which stock is cheaper, TMO, GLW and RGEN?

Thermo Fisher Scientific (TMO) trades on the lowest price-to-earnings ratio (Thermo Fisher Scientific (TMO) 36.5x, Corning (GLW) 57.8x, Repligen (RGEN) 244.2x). On next year's consensus earnings, Thermo Fisher Scientific (TMO) is cheapest (Thermo Fisher Scientific (TMO) 26.1x, Corning (GLW) 35.8x, Repligen (RGEN) 91.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Corning (GLW) grew revenue fastest over the trailing twelve months: Thermo Fisher Scientific (TMO) +7.2%, Corning (GLW) +19.4%, Repligen (RGEN) +16.5%.

Which company is more profitable?

Thermo Fisher Scientific (TMO) has the highest net margin (Thermo Fisher Scientific (TMO) 15.0%, Corning (GLW) 11.2%, Repligen (RGEN) 5.3%). On return on invested capital, Corning (GLW) leads (Thermo Fisher Scientific (TMO) 7.9%, Corning (GLW) 10.4%, Repligen (RGEN) 1.9%).

Which stock has performed better?

Over the past year Corning (GLW) returned the most: Thermo Fisher Scientific (TMO) +17.8%, Corning (GLW) +44.0%, Repligen (RGEN) +7.1%. Over five years, Corning (GLW) compounded fastest (Thermo Fisher Scientific (TMO) +1.9%/yr, Corning (GLW) +26.5%/yr, Repligen (RGEN) -8.4%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Corning (GLW) has the highest dividend yield: Thermo Fisher Scientific (TMO) 0.00%, Corning (GLW) 0.01%, Repligen (RGEN) 0.00%. Repligen (RGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Thermo Fisher Scientific (TMO) 29.8%, Corning (GLW) 74.5%, Repligen (RGEN) 46.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, TMO, GLW and RGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.